You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,142,782


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,142,782
Title:EGFR inhibitors promote axon regeneration
Abstract: Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron.
Inventor(s): He; Zhigang (Wellesley, MA), Koprivica; Vuk (Bethesda, MD)
Assignee: Children\'s Medical Center Corporation (Boston, MA)
Application Number:12/372,988
Patent Claims:1. A method of promoting axonal regeneration of cerebellar granule cells (CGNs), dorsal root ganglion cells (DRGs) or retinal ganglion cells (RGCs) in a patient in need thereof, the method comprising administration of a monoclonal antibody or small molecule Epidermal Growth Factor Receptor (EGFR) inhibitor to thereby contact the CGNs, DRGs, or RGCs with the inhibitor sufficient to promote the axonal regeneration.

2. The method of claim 1 wherein the EGFR inhibitor is a small molecule selected from the group consisting of erlotinib, gefitinib, GW572016, PKI166, CL-1033, EKB-569, and GW2016.

3. The method of claim 1 wherein the monoclonal antibody EGFR inhibitor is selected from the group consisting of cetuximab, panitumumab, TheraCIM, EMD 72000, and MDX447.

4. The method of claim 1 wherein the EGFR inhibitor is administered to the patient by injection.

5. The method of claim 1 wherein the EGFR inhibitor is orally administered to the patient.

6. The method of claim 1 wherein the EGFR inhibitor is contained within an implantable device.

7. The method of claim 1 further comprising the step of detecting a resultant regeneration.

8. The method of claim 1 further comprising the step of detecting a resultant regeneration, wherein the regeneration is detected inferentially by neurological examination.

9. The method of claim 1 wherein the patient has an axon lesion.

10. The method of claim 1 wherein the patient has suffered a traumatic injury.

11. The method of claim 10 wherein administration is within 96 hours of the traumatic injury.

12. The method of claim 10 wherein administration is within 48 hours of the traumatic injury.

13. The method of claim 10 wherein administration is within 24 hours of the traumatic injury.

Details for Patent 8,142,782

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company ERBITUX cetuximab Injection 125084 02/12/2004 ⤷  Try a Trial 2025-07-12
Eli Lilly And Company ERBITUX cetuximab Injection 125084 03/28/2007 ⤷  Try a Trial 2025-07-12
Amgen, Inc. VECTIBIX panitumumab Injection 125147 09/27/2006 ⤷  Try a Trial 2025-07-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.